DB:4TXA

Stock Analysis Report

Executive Summary

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules.


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Therapix Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4TXA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.9%

4TXA

-1.8%

DE Biotechs

0.1%

DE Market


1 Year Return

-87.7%

4TXA

7.2%

DE Biotechs

14.1%

DE Market

Return vs Industry: 4TXA underperformed the German Biotechs industry which returned 7.2% over the past year.

Return vs Market: 4TXA underperformed the German Market which returned 14.1% over the past year.


Shareholder returns

4TXAIndustryMarket
7 Day-0.9%-1.8%0.1%
30 Day-35.7%-2.9%0.2%
90 Day-65.1%5.8%3.3%
1 Year-87.7%-87.7%7.5%7.2%17.6%14.1%
3 Yearn/a42.8%41.2%14.8%4.8%
5 Yearn/a11.6%9.3%22.2%5.4%

Price Volatility Vs. Market

How volatile is Therapix Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Therapix Biosciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Therapix Biosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Therapix Biosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Therapix Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Therapix Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Therapix Biosciences performed over the past 5 years?

-35.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4TXA is currently unprofitable.

Growing Profit Margin: 4TXA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4TXA is unprofitable, and losses have increased over the past 5 years at a rate of -35.3% per year.

Accelerating Growth: Unable to compare 4TXA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4TXA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 4TXA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Therapix Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 4TXA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 4TXA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 4TXA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 4TXA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 4TXA has a low level of unsold assets or inventory.

Debt Coverage by Assets: 4TXA has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 4TXA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 4TXA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -22.9% each year


Next Steps

Dividend

What is Therapix Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4TXA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 4TXA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4TXA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4TXA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4TXA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Ascher Shmulewitz (63yo)

2.3yrs

Tenure

US$446,000

Compensation

Dr. Ascher Shmulewitz, M.D., Ph.D. is the Co-founder and Chief Technology Officer at FLC Ventures. Dr. Shmulewitz serves as Interim Chief Executive Officer of Therapix Biosciences Ltd. since November 1, 2 ...


CEO Compensation Analysis

Compensation vs Market: Ascher's total compensation ($USD446.00K) is about average for companies of similar size in the German market ($USD413.42K).

Compensation vs Earnings: Ascher's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ascher Shmulewitz
Chairman & Interim CEO2.3yrsUS$446.00k0.31% $7.6k
Oz Adler
Chief Financial Officer1.8yrsUS$228.00kno data
Adi Zuloff-Shani
Chief Technology Officer4yrsUS$253.00kno data

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 4TXA's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ascher Shmulewitz
Chairman & Interim CEO2.3yrsUS$446.00k0.31% $7.6k
Stephen Simes
Independent Director3.2yrsUS$52.00kno data
Daniele Piomelli
Member of Scientific Advisory Board0yrsno datano data
Amit Berger
Independent Director5.5yrsno datano data
Raphael Mechoulam
Member of Scientific Advisory Board0yrsno datano data
James Leckman
Member of Scientific Advisory Board3.7yrsno datano data
Kirsten Müller-Vahl
Member of Scientific Advisory Board3.7yrsno datano data
Michael Davidson
Member of Scientific Advisory Board3.7yrsno datano data
Avi Weizman
Member of Scientific Advisory Board3.7yrsno datano data
Michael Bloch
Member of Scientific Advisory Board3.7yrsno datano data

3.7yrs

Average Tenure

65yo

Average Age

Experienced Board: 4TXA's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Therapix Biosciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Therapix Biosciences Ltd.
  • Ticker: 4TXA
  • Exchange: DB
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.664m
  • Listing Market Cap: US$2.468m
  • Shares outstanding: 5.41m
  • Website: https://therapixbio.com

Number of Employees


Location

  • Therapix Biosciences Ltd.
  • Hashahar Tower
  • 16th Floor
  • Givatayim
  • 5320047
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRPXNasdaqCM (Nasdaq Capital Market)YesSPONSORED ADS NEUSUSDSep 2014
4TXADB (Deutsche Boerse AG)YesSPONSORED ADS NEDEEURSep 2014

Biography

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 23:20
End of Day Share Price2020/02/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.